ATE213936T1 - Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon - Google Patents

Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon

Info

Publication number
ATE213936T1
ATE213936T1 AT96920228T AT96920228T ATE213936T1 AT E213936 T1 ATE213936 T1 AT E213936T1 AT 96920228 T AT96920228 T AT 96920228T AT 96920228 T AT96920228 T AT 96920228T AT E213936 T1 ATE213936 T1 AT E213936T1
Authority
AT
Austria
Prior art keywords
colon
coating layer
dosage form
enteric polymer
enterine
Prior art date
Application number
AT96920228T
Other languages
English (en)
Inventor
Gary Robert Kelm
Gary Lee Manring
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE213936T1 publication Critical patent/ATE213936T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96920228T 1995-05-17 1996-05-16 Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon ATE213936T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/442,920 US5686105A (en) 1993-10-19 1995-05-17 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
PCT/US1996/006987 WO1996036322A1 (en) 1995-05-17 1996-05-16 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery

Publications (1)

Publication Number Publication Date
ATE213936T1 true ATE213936T1 (de) 2002-03-15

Family

ID=23758694

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96920228T ATE213936T1 (de) 1995-05-17 1996-05-16 Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon

Country Status (6)

Country Link
US (1) US5686105A (de)
EP (1) EP0825854B1 (de)
JP (1) JP3902229B2 (de)
AT (1) ATE213936T1 (de)
DE (1) DE69619668T2 (de)
WO (1) WO1996036322A1 (de)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6028190A (en) 1994-02-01 2000-02-22 The Regents Of The University Of California Probes labeled with energy transfer coupled dyes
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
FR2745500B1 (fr) * 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
WO1998022096A1 (en) * 1996-11-15 1998-05-28 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US20060029653A1 (en) * 1997-01-29 2006-02-09 Cronk Peter J Therapeutic delivery system
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
BR9916871A (pt) * 1998-11-27 2001-08-21 Kanji Takada Formulação oral para fornecimento de drogas gastrointestinais
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
CN1173695C (zh) * 1999-06-14 2004-11-03 科斯默股份公司 控制释放与掩蔽味道的口服药物组合物
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6365181B1 (en) 2000-04-20 2002-04-02 Gattefosse Corporation Thixatropic gelatin carrier composition
WO2001095912A1 (fr) * 2000-06-16 2001-12-20 Mitsubishi Pharma Corporation Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
DE60237087D1 (de) * 2001-06-01 2010-09-02 Pozen Inc Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004071479A1 (en) 2003-02-12 2004-08-26 Connetics Australia Pty Ltd Film foaming hydroalcoholic foam
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
EP1933852B1 (de) 2005-09-27 2018-12-19 TissueTech, Inc. Amnion-zubereitungen und gereinigte zusammensetzungen und anwendungsverfahren
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20070098746A1 (en) * 2005-11-02 2007-05-03 Nichols William M Multi-layered coating technology for taste masking
EA017290B1 (ru) 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед Композиции на основе ганаксолона
EP2012756A4 (de) * 2006-04-20 2013-01-23 Inventia Healthcare Private Ltd Zusammensetzungen mit mehreren einheiten
US20080014257A1 (en) * 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
US20080090897A1 (en) 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
RU2009111263A (ru) 2006-08-30 2010-10-10 Дэвид Уилльям СМИТ (US) Способ придания одноосевой или многоосевой жесткости экструдированным материалам, а также изделия, получаемые из них
EP2526934B1 (de) 2006-09-22 2015-12-09 Pharmacyclics LLC Hemmer der Bruton-Tyrosinkinase
CN103120653B (zh) 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
CA2699157A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
RU2472791C2 (ru) 2008-08-27 2013-01-20 КалсиМедика Инк. Соединения, модулирующие внутриклеточный кальций
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100068283A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex VIVO modifiable particle or polymeric material medicament carrier
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
DK2421901T3 (en) 2009-04-24 2016-01-11 Tissue Tech Inc Compositions comprising HC-HA complex, and methods of use thereof
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
EP2445499A4 (de) 2009-06-25 2013-02-27 Astrazeneca Ab Verfahren zur behandlung eines patienten mit risiko der entwicklung eines nsaid-assoziierten geschwürs
JP5911799B2 (ja) 2009-08-12 2016-04-27 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ポリマーマトリックスおよび油相を含んで成る免疫調節組成物
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
PT2563776T (pt) 2010-04-27 2016-09-19 Calcimedica Inc Compostos que modulam o cálcio intracelular
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
JP2013530187A (ja) 2010-06-17 2013-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 炎症性疾患を治療するための組成物及び方法。
CA2809830C (en) 2010-08-27 2019-09-10 Calcimedica, Inc. Compounds comprising n-acyl-2-amino-1,3-thiazole for modulating intracellular calcium
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
CA2837878A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
AU2012305915B2 (en) 2011-09-07 2017-09-07 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
CA2845806C (en) 2011-09-13 2019-06-11 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
JP2012107058A (ja) * 2012-02-27 2012-06-07 Warner Chilcott Co Llc 複数のコーティングを有する医薬剤形
WO2013148258A1 (en) 2012-03-29 2013-10-03 Jerome Schentag Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
NZ713828A (en) 2012-06-04 2017-05-26 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN104619352B (zh) 2012-07-11 2022-02-18 组织技术公司 含有hc-ha/ptx3复合物的组合物及其使用方法
WO2014052914A1 (en) 2012-09-28 2014-04-03 University Of Washington Through Its Center For Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2904389C (en) 2013-03-14 2018-09-18 Jerome J. Schentag Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
MX2015012074A (es) 2013-03-15 2016-05-10 Warner Chilcott Co Llc Composicion farmaceutica de mesalamina con multiples elementos de dosis para viabilidad de administracion reducida.
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6165022B2 (ja) * 2013-10-30 2017-07-19 株式会社ファンケル 放出制御型ソフトカプセル剤
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2932609A1 (en) 2013-12-05 2015-06-11 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
SMT202100137T1 (it) 2014-11-07 2021-05-07 Sublimity Therapeutics Ltd Composizioni comprendenti la ciclosporina
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
EP3253766B1 (de) 2015-02-06 2019-09-04 University of Washington Verbindungen und verfahren zur vorbeugung oder behandlung von sensorischem haarzelltod
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
JP2018510138A (ja) 2015-02-27 2018-04-12 カーテナ ファーマシューティカルズ，インク． Ｏｌｉｇ２活性の阻害
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
EA201792496A1 (ru) 2015-05-11 2018-04-30 Абиде Терапеутикс, Инк. Способы лечения воспаления или нейропатической боли
CA2984443A1 (en) 2015-05-20 2016-11-24 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180185378A1 (en) * 2017-01-05 2018-07-05 Cormedix Inc. Antimicrobial delivery system for the prevention and treatment of infections in the colon
HK1256718A1 (zh) 2015-08-31 2019-10-04 药品循环有限责任公司 用於治疗多发性骨髓瘤的btk抑制剂组合
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
JP2019505498A (ja) 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
KR20180101521A (ko) 2016-01-19 2018-09-12 얀센 파마슈티카 엔.브이. Btk 저해제를 포함하는 제형/조성물
MX2018008772A (es) 2016-01-19 2018-11-09 Janssen Pharmaceutica Nv Formulaciones/composiciones que comprenden un inhibidor de btk.
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
EP3442538B1 (de) 2016-04-04 2025-07-23 Sinopia Biosciences, Inc. Behandlung von levodopa-induzierter dyskinesie mit trapidil
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
EP3484862B1 (de) 2016-07-18 2021-09-01 Arthrosi Therapeutics, Inc. Verbindungen, zusammensetzungen und verfahren zur behandlung oder prävention eines symptoms im zusammenhang mit gicht oder hyperurikämie
KR102605329B1 (ko) 2016-08-26 2023-11-22 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
CA3043610A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Crystalline forms of a magl inhibitor
US11273159B2 (en) 2016-11-16 2022-03-15 H. Lundbeck A/S Pharmaceutical formulations
EP3544614B1 (de) 2016-11-28 2025-12-31 Lipocine Inc. Orale testosteron-undecanoat-therapie
TWM553193U (zh) * 2017-06-22 2017-12-21 Guang De Li Capsules Co Ltd 耐酸膜衣膠囊結構
JP7397487B2 (ja) 2017-09-01 2023-12-13 ユニヴァーシティ オブ ワシントン 感覚有毛細胞死を予防または処置するための化合物の結晶形態
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
US10717712B2 (en) 2018-07-27 2020-07-21 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
BR112021010708A2 (pt) 2018-12-06 2021-08-24 Arthrosi Therapeutics, Inc. Formas cristalinas de um composto para tratar ou prevenir gota ou hiperuricemia
KR20210102933A (ko) 2018-12-06 2021-08-20 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방 방법
AU2019417833B2 (en) 2018-12-31 2024-11-07 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
MX2021011081A (es) 2019-03-15 2022-01-18 Unicycive Therapeutics Inc Derivados de nicorandil.
CA3136081A1 (en) 2019-05-03 2020-11-12 Azora Therapeutics, Inc. Compositions comprising indigo and/or an indigo derivative and methods of use thereof
WO2020243393A1 (en) * 2019-05-30 2020-12-03 Vta Labs, Llc Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron's disease and ulcerative colitis
KR20220046623A (ko) 2019-08-12 2022-04-14 메사추세츠 인스티튜트 오브 테크놀로지 치료제의 투여를 위한 물품 및 방법
CN116496279B (zh) 2020-03-26 2025-12-12 希诺皮亚生物科学公司 同位素标记的曲匹地尔衍生物
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
EP4149934A4 (de) 2020-05-11 2024-05-15 Cleave Therapeutics, Inc. Kristalline formen und formulierungen eines vcp/p97-inhibitors
US20240124467A1 (en) 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
CA3204457A1 (en) 2021-01-06 2022-07-14 Ben SESSA Mdma in the treatment of alcohol use disorder
EP4337316A1 (de) 2021-05-11 2024-03-20 Awakn Ls Europe Holdings Limited Therapeutische aminoindanverbindungen und zusammensetzungen
IL309073A (en) 2021-06-03 2024-02-01 Arcadia Medicine Inc Enantiomeric entactogen compounds and methods of their use.
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon
EP4384179A1 (de) 2021-08-11 2024-06-19 Biomea Fusion, Inc. Kovalente inhibitoren der menin-mll-interaktion gegen diabetes mellitus
CN119816500A (zh) 2021-08-20 2025-04-11 拜欧米富士恩公司 用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式
CA3229910A1 (en) 2021-08-23 2023-03-02 Alexander Shulgin Research Institute, Inc. Fluorinated empathogens
CA3229907A1 (en) 2021-08-23 2023-03-02 Nicholas COZZI Deuterated empathogens
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
IL310956A (en) 2021-08-31 2024-04-01 Cerespir Incorporated Co-crystals
CA3230779A1 (en) 2021-09-03 2023-03-09 Paul Daley Asymmetric allyl tryptamines
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
CA3232827A1 (en) 2021-09-25 2023-03-30 Paul Daley Substituted phenylalkylamines
US20250066386A1 (en) 2021-11-09 2025-02-27 Biomea Fusion, Inc. Inhibitors of kras
KR20240128987A (ko) 2021-12-30 2024-08-27 바이오메아 퓨전, 인크. Flt3의 억제제로서의 피라진 화합물
CA3249142A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE
US20250179089A1 (en) 2022-02-16 2025-06-05 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
CN119836422A (zh) 2022-07-06 2025-04-15 奥比兰制药有限公司 S1p受体调节剂的结晶形式
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction
WO2024243402A2 (en) 2023-05-24 2024-11-28 Unicycive Therapeutics Inc. Salt forms of nicorandil derivatives
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2025072556A1 (en) 2023-09-26 2025-04-03 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1260505B (it) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
ES2149250T3 (es) * 1993-04-23 2000-11-01 Novartis Ag Dispositivo para la administracion de medicamentos con liberacion controlada.

Also Published As

Publication number Publication date
DE69619668D1 (de) 2002-04-11
WO1996036322A1 (en) 1996-11-21
US5686105A (en) 1997-11-11
EP0825854B1 (de) 2002-03-06
JPH11505254A (ja) 1999-05-18
JP3902229B2 (ja) 2007-04-04
DE69619668T2 (de) 2002-10-17
EP0825854A1 (de) 1998-03-04

Similar Documents

Publication Publication Date Title
ATE213936T1 (de) Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon
DE69630375D1 (de) Pharmazeutische dosierungsform zur freisetzung im colon
ATE234079T1 (de) Pharmazeutische dosierungsform mit mehrfachen enterischen polymer-überzügenzur abgabe im kolon
CA2268868A1 (en) Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
JP4165905B2 (ja) 胃腸の薬物送達システム
EP1021171B1 (de) Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
US6531152B1 (en) Immediate release gastrointestinal drug delivery system
CA2446712C (en) System for osmotic delivery of pharmaceutically active agents
HUP0002056A2 (hu) Gombaellenes hatóanyaggal és polimerrel bevont magrészt tartalmazó pelletek
IL173078A0 (en) Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form
AU2002303897A1 (en) System for osmotic delivery of pharmaceutically active agents
ATE389389T1 (de) Mehrfach beschichete pharmazeutische dosierungsform
CA2271569A1 (en) Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
CA2271560A1 (en) Pharmaceutical dosage form for colonic delivery
US6635276B1 (en) Oral or mucosal preparation containing an active ingredient, with controlled active ingredient release, and its use
NO992350L (no) Farmas°ytisk doseringsform med multiple enteriske polymerbelegg for avlevering i tykktarmen
NO992349L (no) Farmas°ytisk doseform for avlevering i tykktarmen
CA2243863C (en) Gastrointestinal drug delivery system
BR9612801A (pt) Forma de dosagem farmacêutica com múltiplos revestimentos de polìmeros entéricos para o fornecimento colÈnico.
BR9612800A (pt) Forma de dosagem farmacêutica para distribuição colÈnica.
MXPA00003438A (en) Delayed total release gastrointestinal drug delivery system
HK1017607A (en) Gastrointestinal drug delivery system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties